Company intelligence / Profile preview
Tarveda Therapeutics
Likely Watertown, Massachusetts, United States6sense.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 2
01
Overview
Tarveda Therapeutics develops precision oncology medicines using its proprietary Pentarin® miniature drug conjugate technology. Their lead candidate PEN‑866 targets the activated form of HSP90, which is highly expressed in up to ~75% of solid tumors but dormant in normal tissue. PEN‑866 links an HSP90-binding moiety with a topoisomerase I inhibitor payload SN38, designed for selective delivery and activation within tumors. PEN‑866 has entered Phase 2a clinical trials across various solid tumor types. Additional pipeline candidates target tubulin and PI3Ks using similar miniature drug conjugate approaches[2][4].
- Therapeutic areas
- Oncology
- Modalities
- Miniature drug conjugates ("Pentarin®" platform)Small molecule drug conjugates linked to anti-cancer payloads such as topoisomerase inhibitors and kinase inhibitorsPotential use of radioisotopes in development
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Tarveda Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tarveda Therapeutics.